GelMEDIX: Valuation, Funding & Investors
GelMEDIX is a biotechnology company developing regenerative therapies to restore vision, focusing on cell-based treatments and biomaterials for retinal diseases. The company is advancing GMX-101, an RPE cell therapy for late-stage Geographic Atrophy, and a proprietary injectable hydrogel scaffold platform engineered to optimize delivery, efficacy, and safety of cell and gene therapies.
Leadership & Board
- Current Number of Employees
- 9
- Current LinkedIn Followers
- 1,159
Latest Estimated Valuation
- Total Amount Raised
- $13M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $13M
- Latest Funding Round
- Seed Round
Employee Trend
GelMEDIX had 9 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
GelMEDIX had 1,159 followers as of November 16, 2026. The number of followers increased by 1 (0.09%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Feb 17, 2026 | Seed Round | $13.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Beacon Angels | Seed Round |
| Boston Harbor Angels | Seed Round |
| HTL Biotechnology | Seed Round |
| Safar Partners | Seed Round |
| TiE Boston Angels | Seed Round |
Similar Companies
A snapshot of private companies similar to GelMEDIX, helping you discover and navigate related company profiles.
Related News and Analysis









